

SUPPLEMENTARY TABLE 1. Variations of clinical outcomes in relation to CoQ10-related effects on laboratory measures.

Table shows variations of different clinical outcomes in relation to coenzyme Q10 (CoQ10) effects on laboratory measures. Laboratory and clinical measures repeated within each individual at baseline and after 3 and 6 months were included in mixed-effect linear regression models where we set an interaction term between time and treatment period (post-CoQ10 supplementation visit was at 3 months in Group 1, and at 6 months in Group 2). Coefficients (Coeff), 95% confidence intervals (95%CI) and p-values are reported (p<0.05 is presented as *).

Tertiary endpoints	Coeff	95%CI		p-values
		<i>Lower</i>	<i>Upper</i>	
<u>EDSS</u>				
Uric acid, mg/dL	-0.045	-0.118	0.027	<i>0.224</i>
CellROX cells, %	0.036	-0.059	0.133	<i>0.457</i>
CellROX cells, MFI	0.001	0.001	0.004	<i>0.001*</i>
8-OHdG, ng/mL	0.095	-0.012	0.203	<i>0.084</i>
Eotaxin, pg/mL	0.049	-0.037	0.136	<i>0.268</i>
GM-CSF, pg/mL	0.055	-0.035	0.146	<i>0.232</i>
HGF, pg/mL	0.052	-0.034	0.138	<i>0.236</i>
IFN-γ, pg/mL	0.126	0.031	0.222	<i>0.009*</i>
IL-1α, pg/mL	0.047	-0.038	0.133	<i>0.274</i>
IL-2R, pg/mL	0.057	-0.027	0.141	<i>0.186</i>
IL-4, pg/mL	0.050	-0.036	0.137	<i>0.258</i>
IL-9, pg/mL	0.049	-0.039	0.137	<i>0.275</i>

IL-13 , pg/mL	-0.057	-0.107	-0.006	<i>0.028*</i>
IL-17F , pg/mL	0.044	-0.043	0.133	<i>0.320</i>
MIP-1α , pg/mL	0.050	-0.0351	0.136	<i>0.246</i>
RANTES , pg/mL	0.053	-0.-34	0.141	<i>0.233</i>
TNF-α , pg/mL	0.053	-0.033	0.139	<i>0.229</i>
VEGF , pg/mL	0.049	-0.039	0.137	<i>0.278</i>
<hr/>				
FSS				
Uric acid , mg/dL	-0.430	-2.244	1.383	<i>0.642</i>
CellROX cells , %	0.232	0.071	0,473	<i>0.023*</i>
CellROX cells , MFI	0.241	-2.015	2.498	<i>0.834</i>
8-OHdG , ng/mL	0.045	-1.777	1.868	<i>0.961</i>
Eotaxin , pg/mL	0.072	-1.707	1.853	<i>0.936</i>
GM-CSF , pg/mL	0.484	-1.428	2.397	<i>0.620</i>
HGF , pg/mL	0.060	-1.743	1.864	<i>0.948</i>
IFN-γ , pg/mL	-0.004	-1.891	1.882	<i>0.996</i>
IL-1α , pg/mL	0.006	-1.810	1.822	<i>0.995</i>
IL-2R , pg/mL	-0.029	-1.870	1.810	<i>0.975</i>
IL-4 , pg/mL	0.044	-1.777	1.865	<i>0.962</i>
IL-9 , pg/mL	-0.013	-1.868	1.841	<i>0.989</i>
IL-13 , pg/mL	0.112	-1.708	1.933	<i>0.904</i>
IL-17F , pg/mL	0.004	-1.854	1.862	<i>0.997</i>
MIP-1α , pg/mL	0.024	-1.793	1.843	<i>0.979</i>
RANTES , pg/mL	0.141	-1.721	2.003	<i>0.882</i>
TNF-α , pg/mL	0.006	-1.823	1.836	<i>0.995</i>

VEGF , pg/mL	-0.070	-1.926	1.785	0.941
<u>BDI</u>				
Uric acid , mg/dL	-1.665	-3.326	-0.004	0.049*
CellROX cells , %	-0.205	01.664	1.253	0.782
CellROX cells , MFI	-0.145	-1.766	1.475	0.860
8-OHdG , ng/mL	0.439	-0.841	1.720	0.501
Eotaxin , pg/mL	0.424	-0.867	1.716	0.520
GM-CSF , pg/mL	0.546	-0.833	1.926	0.438
HGF , pg/mL	0.431	-0.864	1.727	0.514
IFN-γ , pg/mL	0.322	-0.993	1.637	0.631
IL-1α , pg/mL	0.388	-0.908	1.684	0.557
IL-2R , pg/mL	0.310	-0.979	1.599	0.637
IL-4 , pg/mL	0.390	-0.894	1.674	0.552
IL-9 , pg/mL	0.232	-1.053	1.523	0.720
IL-13 , pg/mL	0.291	-1.000	1.583	0.658
IL-17F , pg/mL	0.271	-1.028	1.572	0.682
MIP-1α , pg/mL	0.365	-0.922	1.652	0.578
RANTES , pg/mL	0.170	-1.142	1.483	0.799
TNF-α , pg/mL	0.362	-0.936	1.662	0.584
VEGF , pg/mL	0.166	-1.111	1.443	0.799
<u>VAS for pain</u>				
Uric acid , mg/dL	-0.230	-0.816	0.355	0.441
CellROX cells , %	0.254	-0.329	0.838	0.393
CellROX cells , MFI	0.015	-0.629	0.660	0.963

8-OHdG , ng/mL	0.124	-0.374	0.623	<i>0.625</i>
Eotaxin , pg/mL	0.143	-0.370	0.657	<i>0.585</i>
GM-CSF , pg/mL	0.262	-0.267	0.792	<i>0.332</i>
HGF , pg/mL	0.156	-0.362	0.674	<i>0.555</i>
IFN-γ , pg/mL	0.201	-0.330	0.733	<i>0.458</i>
IL-1α , pg/mL	0.127	0.004	0.251	<i>0.043*</i>
IL-2R , pg/mL	0.164	-0.357	0.687	<i>0.537</i>
IL-4 , pg/mL	-0.075	-0.141	-0.009	<i>0.024*</i>
IL-9 , pg/mL	0.125	-0.395	0.646	<i>0.636</i>
IL-13 , pg/mL	0.178	-0.335	0.692	<i>0.497</i>
IL-17F , pg/mL	0.140	-0.377	0.658	<i>0.594</i>
MIP-1α , pg/mL	0.064	-0.004	0.133	<i>0.066</i>
RANTES , pg/mL	0.001	0.001	0.001	<i>0.009*</i>
TNF-α , pg/mL	0.149	-0.366	0.664	<i>0.570</i>
VEGF , pg/mL	0.139	-0.385	0.664	<i>0.603</i>